23andMe Investor Presentation Deck

'610 Differentiation: Inhibition of CD200R1 Has the Potential to Address Resistance to Anti-PD1 Therapies IFNY fold change relative to isotype Y Blocking the CD200R1 pathway enhanced IFNy production from SEB-stimulated PBMCs compared to isotype control and anti-PD1 in the majority of samples tested Colorectal Endometrial 1 Endometrial 2 Endometrial 3 Lung Ovarian Melanoma Prostate Pancreatic Isotype 23ME-00610 Anti-PD-1 PBMC, peripheral blood mononuclear cell; PD-1, programmed death-1; SEB, staphylococcal enterotoxin B. PBMCs from each respective patient were incubated with 100 nM of 23ME-00610, anti-PD-1, or isotype control. Cells were stimulated with SEB. IFNy levels were determined by enzyme-linked immunosorbent assay. Mean biologic triplicates were normalized to isotype control. * p-value<=0.05 compared to control Copyright © 2024 23andMe, Inc. 23andMe 28

View entire presentation